Dr. Reddy’s Laboratories Limited has entered a strategic collaboration with Shanghai Henlius Biotech, Inc. for the development and commercialization of HLX15, a biosimilar to Darzalex® and Darzalex Faspro®, used in the treatment of multiple myeloma. Dr. Reddy’s Swiss, a wholly-owned subsidiary of the company, will hold exclusive rights for the subcutaneous and intravenous formulations of HLX15 across the U.S. and European markets.
The deal involves a total consideration of up to $131.6 million, including an upfront payment of $33 million and subsequent milestone-based payments. Henlius will manage the development, manufacturing, and commercial supply of HLX15, while Dr. Reddy’s will leverage its commercial infrastructure in the U.S. and Europe to drive distribution and patient access. Additionally, Henlius will be entitled to royalties on the annual net sales.
This collaboration is expected to strengthen Dr. Reddy’s biosimilar portfolio in regulated markets, complementing its existing oncology and biosimilar launches. The agreement also emphasizes Dr. Reddy’s focus on ensuring global access to affordable treatment options in critical therapeutic areas like oncology.
Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions.
